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Human papillomavirus (HPV) is a common sexually 
transmitted virus and is causally associated with cervical 
cancerous and pre-cancerous lesions.1  HPV types infecting 
the genital tract are broadly divided into high- and low-risk 
types on the basis of their association with cervical cancer.  The 
low-risk types are causally associated with genital warts.  In an 
analysis of pooled data from 11 case-control studies, Munoz et 
al.2 compared HPV types in cancer cases with control women 
and showed that 15 types, HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73 and 82, were classified as high-risk types and a 
further three types, HPV 26, 53 and 66, were probable high-risk 
types.  The Digene Hybrid Capture 2 HPV test (HC2) (Digene, 
Gaithersburg, MD, USA) is the only commercially available 
assay system for HPV detection and the only test approved by 
the US Food and Drug Administration (FDA).  The test detects 
13 high-risk HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59 and 68) and 5 low-risk types.
The Papanicoloau (Pap) smear test is the standard cytology 
screening method and is used worldwide because it is a 
comparatively inexpensive and simple procedure.  The test is, 
however, only moderately accurate3 and additional methods 
are being sought in order to improve screening strategies.  A 
multi-centre, randomised clinical trial was done in the USA 
to study the management of abnormal squamous cells of 
unknown significance (AS-CUS) and low-grade squamous 
intraepithelial lesions (LSIL) by one of three methods: 
immediate colposcopy, cytological follow-up and triage by 
HPV.4 The findings of this trial are summarised as follows: 
HPV testing was not useful in the triage of women with LSIL, 
as the prevalence of HPV was too high.  However, in women 
with AS-CUS cytology, HPV triage proved useful, as it was as 
sensitive as immediate colposcopy and halved the number of 
referrals for colposcopy.4 
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Objectives and design. Human papillomavirus (HPV) is 
causally associated with cervical cancer. Using the Digene 
Hybrid Capture 2 high-risk HPV test (HC2), we investigated 
the prevalence of high-risk HPV in cervical specimens, and 
compared results with those of Papanicolaou (Pap) smears 
taken concurrently.
Subjects and setting. Cervical specimens were obtained from 
women attending hospitals/community health centres in 
the Western Cape province of South Africa.  They were 
participating in a case-control study of the association of 
hormonal contraceptives and invasive cervical cancer. 
Results. Of 1 491 women tested, 254 (17%) were HPV DNA 
positive.  The age-specific prevalence of HPV was 36/97 
(37.1%) in those aged < 30 years, 78/369 (21.1%) in those 
aged 30 - 39 years, 78/603 (12.9%) in those aged 40 - 49 
years and 62/422 (14.7%) in those aged 50 - 59 years.  In 
women with normal cytology the prevalence of HPV was 
10.9% (138/1 264); in those with abnormal squamous cells 
of unknown significance (AS-CUS) it was 30.8% (36/117); in 
those with low-grade squamous intraepithelial lesions (LSIL) 
it was 63.2% (36/57), and in those with high-grade squamous 
intraepithelial lesions (HSIL) it was 83% (44/53).  The odds 
ratio between HPV and HSIL in women aged 40 - 59 years was 
57.1 (confidence interval 22.4 - 170.7).
Conclusions. HC2 detected a high prevalence of HPV (17%) in 
this population.  Most women with HSIL (83%) were positive, 
indicating that HPV testing of AS-CUS women may aid in 
management.  When costs decrease, HC2 could be introduced 
as an adjunct to Pap smears in identifying women at risk 
for high-grade cervical disease and could be useful in the 
maintenance of cervical health in those who remain Pap smear 
negative.
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An ideal HPV test to facilitate a cervical screening/
cervical cancer prevention campaign in less-developed and 
resource-poor countries would be one that is simple, quick 
and cost-effective.  HPV testing has the potential to improve 
the negative predictive value of cytology (proportion of 
women without cervical abnormalities who test Pap smear 
negative), thus allowing screening intervals to be increased.5  
However, HPV tests can show a high false-positive rate for 
cervical disease (the labelling of those with normal cytology 
as diseased), which could result in large numbers of women 
with cervical HPV infection being referred for colposcopy; 
an entirely unacceptable situation, especially in low-resource 
settings.  This study therefore compared HC2 with Pap smear 
cytology for the detection of cervical disease in South African 
women.
Methods
Subjects and specimens
For cytology (Pap smear) and HPV testing (cervical brushings), 
specimens (concurrently sampled) were obtained from women 
attending hospitals and community health centres in the 
Western Cape province of South Africa between January 1998 
and December 2001.  These women were recruited as controls 
in a case-control study to investigate associations between 
hormonal contraceptives and invasive cervical cancer.6  The 
study was confined to coloured and black women; we were 
unable to study white women because invasive cervical cancer 
is uncommon in this ethnic group.  To be eligible for inclusion, 
the women had to be less than 60 years of age and had to 
have lived within 150 km of Cape Town during the preceding 
6 months.  Of the 1 654 women approached, 107 refused to 
participate (38 because they had recently had a Pap smear) and 
1 sample was mislaid.  A further 55 were excluded, 7 because 
they were found to have cervical cancer, and 48 because of 
unsatisfactory Pap smear results.  The final 1 491 women were 
aged between 22 and 59 years  (median age 44 years).
Pap smear results were obtained from archived records 
(Table I).  Cervical abnormalities were defined into four 
categories: negative (no abnormal cytology), AS-CUS, LSIL and 
high-grade squamous intraepithelial lesions (HSIL).  Normal 
cytology was found in 1 264 (84.8%) of the 1 491 women, AS-
CUS in 117 (7.8%), LSIL in 57 (3.8%) and HSIL in 53 (3.6%).
HPV testing
 Cervical scrapings were assayed for high-risk HPV types using 
the HC2 test.  This enabled the detection of high-risk HPV 
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.  The 
assay denaturation protocol was modified: after mixing the 
cervical specimen for 5 seconds, 70 μl of the fluid was removed 
from the specimen tube and mixed with 35 μl of denaturation 
agent.  The remainder of the specimen was stored at –70°C for 
future use.  Test results were classified as positive according to 
the manufacturer’s instructions.
Data analysis
The correlations between HPV infections and Pap smear-
defined cervical abnormalities were calculated using odds 
ratios (ORs) (with confidence intervals (CIs)) and kappa 
values.  ORs and the Cornfield and Exact 95% CIs for ORs 
were calculated using Epi Info Version 5 (Centers for Disease 
Control, Epidemiology Program Office, Atlanta, Ga, USA).  
The test for a linear trend between increasing severity of 
cervical lesions and increasing prevalence of HPV infection 
was calculated using Epi Info Version 5 and text information 
provided by Altman.7 Kappa values were calculated according 
to text information provided by Fleiss.8
Results
Of the 1 491 women examined by the hybrid capture test, 254 
(17%) were found to be high-risk HPV DNA positive.  The 
black women had a significantly (p = 0.004) higher prevalence, 
82/376 (21.8%), than the coloured women, 172/1 115 (15.4%).  
The age-specific prevalence of high-risk HPV was 36/97 
(37.1%) in those aged less than 30 years, 78/369 (21.1%) in 
those aged 30 - 39 years, 78/603 (12.9%) in those aged 40 - 49 
years and 62/422 (14.7%) in those aged 50 - 59 years (Fig. 1).  
The prevalence of high-risk HPV declined with age but then 
increased slightly in those aged 50 and older.
The prevalence of high-risk HPV increased with the severity 
of cervical abnormality, being 10.9% (138/1 264) in women 
with normal cytology, 30.8% (36/117) in those with AS-CUS, 
63.2% (36/57) in those with LSIL and 83.0% (44/53) in those 
with HSIL (Fig. 2).  Of the 254 HC2-positive women, 54.3% 
(138) were graded as having normal cervical cytology, 14.2% 
(36) as AS-CUS, 14.2% (36) as LSIL and 17.3% (44) as HSIL.
Table I. Age distribution of Pap smear results 
Age  Negative       AS-CUS      LSIL    HSIL 
(yrs)  (% (N/total))  (% (N/total))   (% (N/total))   (% (N/total))
21 - 39  82.8 (386/466)    7.9 (37/466)  6.0 (28/466)  3.2 (15/466)
40 - 59  85.7 (878/1 025)    7.8 (80/1 025)  2.8 (29/1 025)  3.7 (38/1 025)
Totals  84.8 (1 264/1 491)    7.8 (117/1 491)  3.8 (57/1 491)  3.6 (53/1 491)
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The OR for an association between high-risk HPV and AS-
CUS was 4.4 (CI 2.1 - 9.3) and 3.3 (CI 1.8 - 6.1) in women aged 
21 - 39 and 40 - 59 years, respectively, for LSIL 22.6 (CI 7.9 - 
78.3) and 10.0 (CI 4.4 - 22.9), respectively, and for HSIL 20.5 
(CI 5.3 - 115.3) and 57.1 (CI 22.4 - 170.7), respectively (Table 
II).  The x2 test for linear trend showed a relationship between 
increasing severity of disease of cervical lesions and increasing 
prevalence of HPV (p ≥ 0.00001). Calculated kappa values 
of associations between the Pap smear and hybrid capture 
(with comparisons stratified according to age) showed low 
agreement beyond chance (κ < 0.40) in all categories of Pap 
smear cytology, except for women with HSIL in the 40 - 59-year 
age group (κ = 0.40) (Table III).
Discussion
Pap smears have been instrumental in reducing cervical cancer 
incidence worldwide, but they nevertheless have documented 
limitations.  The accuracy of the Pap smear test is variable, 
with the suggestion that it is less efficient at discriminating 
between the diseased and those without disease than is 
generally believed.3  However, screening with the Pap smear 
test requires little in terms of consumables and equipment, and 
it is an established and widely practised method of screening 
for cervical abnormalities.  By comparison, HC2 assays are 
grounded in a clearly defined and stringently standardised 
testing system.  HC2 specimen collection is a relatively simple 
procedure, specimen transport and storage parameters are 
robust, assay results across testing centres are designed to be 
comparable, and test findings can easily be used in concert 
with other cervical screening tests.
However, there are several reasons why the use of HC2 in 
cervical disease diagnosis has limitations.  Firstly, HC2 assays 
provide evidence of HPV presence and not of cervical disease.  
Furthermore, while high-risk HPV infection is necessary for the 
development of cervical neoplastic disease, severe neoplasia 
generally develops only after a lengthy period of time and only 
in a small proportion of HPV-infected women.  The results 
presented here emphasise the latter in the prevalence figures 
of high-risk HPV in all women, namely 17% (254/1 491), 
compared with the prevalence of LSIL/HSIL, namely 7.4% 
(110/1 491) (Fig. 2).  Furthermore, a single HC2 sample assay 
cannot determine whether high-risk HPV infection is of a 
persistent nature, persistence being a necessary factor in the 
development of cervical neoplasia.9
A further limiting feature of this particular study was that 
HC2 specimens (testing for risk factor), and Pap smears (testing 
for outcome), were taken simultaneously, with conclusions 
being drawn from what was essentially a cross-sectional study 
design, where findings are only intended to be exploratory and 
suggestive by nature.  Further, in comparing HC2 with the Pap 
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Fig. 1. The prevalence of high-risk HPV in women according to age.
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Fig. 2. The prevalence of high-risk HPV in all women, in women with 
normal cytology, and in women with AS-CUS, LSIL or HSIL.
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Table II. Odds ratios showing the association of high-risk HPV and Pap smear results, according to age
Age        AS-CUS             LSIL          HSIL
(yrs)  OR      CI  OR        CI             OR      CI
21 - 39  4.4  2.1 - 9.3  22.6    7.9 - 78.3* 20.5  5.3 - 115.3*†
40 - 59       3.3  1.8 - 6.1     10.0     4.4 - 22.9   57.1  22.4 - 170.7*†
*CIs according to Exact method, otherwise according to Cornfield. 
†CI excessively wide owing to the small number of values in the relevant cell.
OR = odds ratio; CI = confidence interval.
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smear, which is known to be an imperfect measure of cervical 
neoplasia, sensitivity, specificity and positive predictive values 
for HC2 might tend to be lower than expected compared 
with HC2 comparisons against a true gold standard, namely 
colposcopically mediated biopsy/histology.  Lastly, the cost 
of the essential laboratory equipment, trained laboratory staff 
and HC2 consumables needed, might prove prohibitively high 
for public health service HPV screening initiatives.  HC2 too, 
unlike the Pap smear test, is a relatively novel assay in this 
country, with few laboratory nodes available for the testing of 
specimens or for the training of assay staff.
Despite these limitations, the findings presented here, using 
a novel technique, have much in common with findings from a 
variety of similar and more stringently designed international 
studies.  Age was shown to be a factor in cervical disease 
and in HPV infection, with a high prevalence of HPV in the 
younger age group, then a steady decline until the age of 50, 
then a slight increase in those older than 50 years.  This rise in 
older women is in keeping with findings from other studies.10 
It was therefore clearly illustrated that there are strong 
relationships between age, HPV prevalence and severity of 
cytological disease.  ORs (Table II) of the association between 
HPV, cervical abnormalities and age provide an indication 
of what is perhaps the true relevance of HPV DNA testing, 
namely that HPV findings are a measure of the risk of current 
or future cervical abnormalities and any risk assessment must 
be based on a personal/medical history profile of the woman 
concerned, in which age and lifestyle are important factors.  
For instance, in women older than 30 years with AS-CUS/LSIL, 
a positive HPV test can be regarded as a credible measure 
of the risk of cervical disease.  In this study the prevalence 
of HPV as measured by HC2 was 30.8% in cases of AS-CUS 
and 63.2% in LSIL.  It has been reported that only 5 - 10% of 
women with AS-CUS harbour underlying serious cervical 
disease, but of all HSILs identified in screening populations, 
one-third are identified following further investigations from 
AS-CUS results.11  For women with AS-CUS cytology, HPV 
triage showed a sensitivity equal to immediate colposcopy, and 
resulted in a halving of colposcopic referrals.4  Following these 
and other findings, the US FDA has approved HC2 for use in 
AS-CUS triage.
With regard to HPV tests and the management of LSIL, 
63.1% of LSILs in this study were HC2 positive, which, 
as shown in similar studies, limits its use in management 
decisions.12  Generally it is accepted that HPV-positive status in 
a person aged above 30 years or who is immune compromised 
or HIV positive13 would be an association requiring further 
investigation.
The prevalence of HSIL in this study rose with age, whereas 
that of HPV decreased.  In women aged over 40 years, 
therefore, HPV-positive status raises the measure of risk.  Yet 
kappa values calculated on data stratified according to age 
and cervical condition (Table III) only yielded a value of 
0.40 in the HSIL category for women between the ages of 40 
and 59 years (moderate agreement beyond chance).  These 
results mean that although there was a strong association 
between HPV positivity and the degree of abnormality of the 
Pap smear, the kappa results at best indicate an imprecise 
agreement between these two tests.  A positive HC2 test in an 
older (and especially a previously unscreened) person should 
therefore initiate vigorous further investigations.  Conversely, 
the high rates of negative HC2 findings show a diagnostically 
useful association between cervical health and the absence of 
HPV.  The results from older women showed there was a high 
probability that a negative HC2 test result accurately reflected 
absence of HSIL.  The results of this study are in keeping with 
other findings in that where women routinely test both HPV 
negative and cytologically normal, the number of screening 
tests could be reduced according to the recommended 
management policy guidelines.  Moreover, negative HC2 
tests after treatment for cervical neoplasia also indicate a 
good probability that there has been no resurgence of cervical 
disease.14  It is worth noting that since the time of progression 
from detectable LSIL to preclinical invasive cancer is generally 
12 - 13 years, Meijer et al.15 have proposed re-screening every 
8 years in cytologically normal and HPV-negative women.  To 
summarise, negative HC2 and Pap smear test surveillance has 
important implications in the assurance of continuing cervical 
health and in the prevention of resurgence of cervical disease 
after treatment.
Conclusion
Many of the findings in this study mirror those from similar 
studies.16  The strong association between cervical high-risk 
HPV infection, cervical abnormality and age indicates that HC2 
is a useful addition to screening for HPV-associated cervical 
disease.  Aside from its use in conjunction with the Pap smear, 
HC2 might have a use in increasing the resolving power of 
other diagnostic and management options, such as direct 
inspection and immediate treatment techniques, especially 
under busy clinic conditions.  The development of vaccines 
showing protection against incident and persistent HPV-16 
and HPV-18 infections, and incident HPV-31 and HPV- 45 
infections, is advanced.17 The prevalence of oncogenic HPV 
types in women with normal cytology in this study was 10.9% 
(Fig. 2). These results indicate that cervical oncogenic HPV 
prevalence is significant in South Africa.  The current HC2, 
Table III. Kappa values showing the agreement beyond 
chance between  HC2 and Pap smear results, according to 
age 
Age (yrs)              AS-CUS            LSIL               HSIL
  21 - 39      0.19                0.32                0.22 
  40 - 59      0.15                0.20                0.40 
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together with other HPV tests, will be useful in monitoring the 
epidemiological impact of a vaccination programme.  Clinically, 
HC2 will be used to test for oncogenic HPV types in women 
who are already infected, before vaccines become available.18 
Conversely, the analysis presented here of the differences 
between HPV prevalence, that of Pap smear cytology and the 
dynamics of cervical disease, would rule out the use of HC2 in 
its current form as an alternative primary screening method for 
cervical abnormalities.  Moreover, until the cost of HC2 testing 
is substantially reduced, it is not practical to introduce the test 
into the public sector as part of a primary screening strategy.  
Currently HC2 testing would be of immediate clinical use for 
the triage of women with AS-CUS smears and in the follow-up 
surveillance of treated cervical disease.  
HC2 presents an additional procedure that, in combination 
with other methods, can aid in the risk assessment of current 
and future cervical disease.  In South Africa there is a pressing 
need for additional viable, practical and innovative screening 
aids for cervical cancer and pre-cancer, which could include 
HC2 testing. 
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